Immunogenicity, security and protection against small ruminant lentivirus (SRLV) challenge in sheep, induced by intranasal immunization with a recombinant Sendai virus vector expressing SRLV gag-P25
Gómez, Álex (Universidad de Zaragoza. Instituto Agroalimentario de Aragón-IA2)
Glaria, Idoia (Instituto de Agrobiotecnología (CSIC-Gobierno de Navarra))
Moncayola, Irati (Instituto de Agrobiotecnología (CSIC-Gobierno de Navarra))
Echeverría, Irache (Universidad Pública de Navarra. Departamento de Agronomía, Biotecnología y Alimentación)
Rodríguez-Largo, Ana (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals)
de Blas, Ignacio (Universidad de Zaragoza. Instituto Agroalimentario de Aragón-IA2)
Pérez, Estela (Universidad de Zaragoza. Instituto Agroalimentario de Aragón-IA2)
Pérez, Marta (Universidad de Zaragoza. Departamento de Anatomía, Embriología y Genética Animal)
Villanueva-Saz, Sergio (Universidad de Zaragoza. Instituto Agroalimentario de Aragón-IA2)
Lee, Benhur (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
de Diego, Alicia (Centro de Investigación Biomédica de Aragón)
de Miguel, Ricardo (AnaPath Services GmbH)
Luján, Lluís (Universidad de Zaragoza. Instituto Agroalimentario de Aragón-IA2)
Reina, Ramsés (Instituto de Agrobiotecnología (CSIC-Gobierno de Navarra))

Data:	2025
Resum:	Small ruminant lentiviruses (SRLV) are responsible for significant economic losses in sheep and goat farming; however, effective vaccination strategies remain unavailable. This study evaluated the immunogenicity, safety, and protective efficacy of a recombinant Sendai virus vector (SeV) expressing SRLV gag -P25 (rSeV-GFP-P25) in lambs. Twenty-one SRLV-negative lambs were divided into three groups and inoculated intranasally thrice with culture medium (group 1); SeV-GFP (group 2) or rSeV-GFP-P25 (group 3). Lambs were challenged with homologous SRLV at 16 weeks post-first immunization. Clinical and hematological parameters, antibody responses, SRLV viral loads in peripheral blood mononuclear cells (PBMCs) and target tissues, histopathological and histomorphometric analyses, assisted with artificial intelligence, of interstitial pneumonia were assessed. No clinicopathological alterations were observed, except for a transient temperature increase in group 3 post-first immunization. Group 2 showed mild SeV-neutralizing antibodies, while rSeV-GFP-P25 (group 3) induced negligible SRLV-specific antibody responses. Group 3 exhibited higher SRLV DNA copies in PBMCs but lower in most SRLV target tissues compared to control groups, with no SRLV DNA detected in spleen and bone marrow. Histomorphometry revealed reduced alveolar septal thickening in group 3, indicating partial protection against early SRLV-associated interstitial pneumonia. These results warrant further investigation into cellular immunity and long-term protection.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Sendai ; Viral vector ; Vaccine ; Intranasal ; Small ruminant lentiviruses
Publicat a:	The Veterinary Quarterly, Vol. 45 (september 2025) , p. 1-16, ISSN 1875-5941

DOI: 10.1080/01652176.2025.2556492
PMID: 40959881

17 p, 4.6 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats